Clik here to view.
テラヴェクティスがキュリー研究所から合成ヒト化ナノボディーライブラリーの独占使用権を確保し、専有的な免疫療法プラットフォームを強化
パリ （ビジネスワイヤ） — レンチウイルスベクターを使用した治療用ワクチンとT細胞療法の開発におけるパイオニア企業のテラヴェクティスは、フランス・パリのキュリー研究所が開発した合成ヒト化ラクダ由来ナノボディーライブラリーに対する独占的ライセンスを取得したと、本日発表しました。 THERAVECTYS secures exclusive access to a synthetic...
View ArticleClik here to view.
Guided Therapeutics Completes Interim Financing; Initiating Distribution of...
NORCROSS, Ga. Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), announced today it has completed the sale of 4.0 million shares of our common stock and warrants to purchase an additional 2.0...
View ArticleClik here to view.
PerkinElmer在中国上市首款全自动遗传疾病筛查系统
马萨诸塞州沃尔瑟姆和上海 (美国商业资讯) — PerkinElmer, Inc.是一家专注于改善人类及环境健康和安全的全球领先公司，该公司今天宣布，该公司的基因筛查处理器(Genetic Screening Processor®, GSP)仪器和GSP新生儿hTSH试剂盒已获得中国食品药品监督管理局(CFDA)的上市许可证。...
View ArticleClik here to view.
4SC Signs Licensing and Development Agreement with Menarini for Resminostat...
SINGAPORE 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer and autoimmune diseases, and Singapore based Menarini Asia-Pacific...
View ArticleClik here to view.
Baxter Submits Application to Japan’s MHLW for Approval of BAX 855, Extended...
DEERFIELD, Ill. Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a new drug application (NDA) to Japan’s Ministry of Health, Labour and Welfare for the approval of...
View ArticleClik here to view.
MTTI and National Health Research Institutes present a Novel Cancer...
WEST CHESTER, Pa. Molecular Targeting Technologies, Inc. (MTTI) and National Health Research Institutes (NHRI), Taiwan announced today that they will present results on a new cancer therapeutic at...
View ArticleClik here to view.
Avipep’s Clinical Study of AVP-04 in Ovarian and Prostate Cancer Selected for...
MELBOURNE, Australia & PHILADELPHIA, Pa. Australian antibody company Avipep has today announced the clinical results of the imaging study of AVP04, the company’s treatment for advanced prostate...
View ArticleClik here to view.
St. Jude Medical Announces Intent to Acquire Spinal Modulation, Inc.
ST. PAUL, Minn. St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced it has exercised the company’s exclusive option to acquire Spinal Modulation, Inc., developer of...
View ArticleClik here to view.
4SCが日本を除くアジア太平洋地域を対象にレスミノスタットのライセンス／開発契約をメナリーニと締結
シンガポール （ビジネスワイヤ）– がん／自己免疫疾患向けの低分子標的治療薬を創薬・開発している4SC AG（フランクフルト、プライム・スタンダード：VSC）と、シンガポールに拠点を置くメナリーニ・アジアパシフィック・ホールディングス（メナリーニAP）は、日本を除くアジア太平洋地域を対象に4SCの抗がん化合物レスミノスタットのライセンス／開発提携契約を締結したと発表しました。...
View ArticleClik here to view.
Presbia Announces the Start of Commercialization of the Presbia Flexivue...
DUBLIN Presbia PLC (NASDAQ: LENS), an ophthalmic device company that has developed and is currently marketing Presbia Flexivue Microlens™, a proprietary optical lens implant for treating presbyopia,...
View ArticleClik here to view.
全球性试验显示，在急性缺血性卒中治疗中加用美敦力的Solitaire™器械支架除栓术可改善神经系统转归
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 都柏林 (美国商业资讯)–于《新英格兰医学杂志》(NEJM)在线发表、并在欧洲卒中组织会议上呈报的两项全球性试验显示，在现有药物治疗中加用Solitaire™ 器械支架除栓术，可显著减轻卒中患者的残疾。这些试验证实了同样发表于NEJM的三项既往试验的结果。...
View ArticleClik here to view.
Astellas Pharma and Potenza Therapeutics Partner to Build a Portfolio of...
TOKYO & CAMBRIDGE, Mass. Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today announced an...
View ArticleClik here to view.
New GloMax® Explorer Integrates Optimized Promega Protocols and Allows...
MADISON, Wis. Promega Corporation announces the launch of GloMax® Explorer Multimode Detection System, a flexible multimode reader for luminescence, fluorescence and absorbance detection integrated...
View ArticleClik here to view.
Ocata Therapeutics Announces Positive Results in Treating Macular...
MARLBOROUGH, Mass. Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced that a study has been published that includes...
View ArticleClik here to view.
Successful Closure of the TOB for Cellular Dynamics International Inc., a...
TOKYO On April 3, 2015, FUJIFILM Holdings Corporation (President: Mr. Shigehiro Nakajima) (hereafter, “Fujifilm”) launched a tender offer bid (hereafter, “TOB”) offering USD 16.50 per share for the...
View ArticleClik here to view.
Acucela Shareholders Elect New Board Members
SEATTLE Acucela Inc. (TOKYO: 4589) (“Acucela” or the “Company”), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and...
View ArticleClik here to view.
Garvan Institute of Medical Research Selects BiOptix Biosensor For Drug...
BOULDER, Colo. Garvan Institute of Medical Research, one of Australia’s leading biomedical research institutes, announced today they have selected the BiOptix 404pi for their drug discovery...
View ArticleClik here to view.
Generon Received US FDA Clearance to Initiate Phase IIa Study With F-652, a...
SHANGHAI Generon Corporation, a leading biotech company in China, today announced that it received US FDA clearance of the IND for a Phase IIa study, entitled “Recombinant Human...
View ArticleClik here to view.
New Promega NanoBRET™ Technology Enables Real-Time Monitoring of Protein...
MADISON, Wis. Promega Corporation announces the launch of NanoBRET™ Protein Interaction Assays, which use a new Bioluminescence Resonance Energy Transfer (BRET) technology that enables scientists to...
View ArticleClik here to view.
エリテック、ALL対象とする当社の治験用新薬利用範囲拡大プログラム（EAP）で年次DSMB評価の好結果を発表
仏リヨン （ビジネスワイヤ） — 急性白血病および医療ニーズが満たされていないその他の腫瘍適応症を対象に革新的な「腫瘍飢餓化」治療薬の開発に当たっているフランスのバイオ製薬企業エリテック・ファーマ（Paris:ERYP）（ADR:EYRYY）（Euronext Paris – ERYP; OTC US –...
View Article